These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1654940)

  • 1. Purification and immunological characterization of HPLC-purified pertussis toxin subunits.
    Chong P; Cockle S; Boux H; Klein M
    Biochem Cell Biol; 1991; 69(5-6):336-40. PubMed ID: 1654940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of pertussis toxin analogs containing mutations in B-oligomer subunits.
    Loosmore S; Zealey G; Cockle S; Boux H; Chong P; Yacoob R; Klein M
    Infect Immun; 1993 Jun; 61(6):2316-24. PubMed ID: 8500874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective activities in mice of monoclonal antibodies against pertussis toxin.
    Sato H; Sato Y
    Infect Immun; 1990 Oct; 58(10):3369-74. PubMed ID: 1698179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pertussis toxin S1 mutant with reduced enzyme activity and a conserved protective epitope.
    Burnette WN; Cieplak W; Mar VL; Kaljot KT; Sato H; Keith JM
    Science; 1988 Oct; 242(4875):72-4. PubMed ID: 2459776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-step purification of pertussis toxin and its subunits by heat-treated fetuin-sepharose affinity chromatography.
    Chong P; Klein M
    Biochem Cell Biol; 1989 Jul; 67(7):387-91. PubMed ID: 2477043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of mutant strains producing pertussis toxin cross reacting materials.
    Sato Y; Sato H; Chazono M; Ginnaga A; Tamura C
    Dev Biol Stand; 1991; 73():93-107. PubMed ID: 1778339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pertussis toxin analog with reduced enzymatic and biological activities is a protective immunogen.
    Kimura A; Mountzouros KT; Schad PA; Cieplak W; Cowell JL
    Infect Immun; 1990 Oct; 58(10):3337-47. PubMed ID: 2119344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of antibodies elicited by immunization with pertussis toxin.
    Kaslow HR; Schlotterbeck JD; Gotto J
    Dev Biol Stand; 1991; 73():143-50. PubMed ID: 1778308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of amino acid residues essential for the enzymatic activities of pertussis toxin.
    Locht C; Capiau C; Feron C
    Proc Natl Acad Sci U S A; 1989 May; 86(9):3075-9. PubMed ID: 2470088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADP-ribosyltransferase activity of pertussis toxin and immunomodulation by Bordetella pertussis.
    Black WJ; Munoz JJ; Peacock MG; Schad PA; Cowell JL; Burchall JJ; Lim M; Kent A; Steinman L; Falkow S
    Science; 1988 Apr; 240(4852):656-9. PubMed ID: 2896387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elucidation of linear epitopes of pertussis toxin using overlapping synthetic decapeptides: identification of a human B-cell determinant in the S1 subunit indicative of acute infections.
    Raupach B; Schmidt MA
    Microb Pathog; 1994 Oct; 17(4):213-26. PubMed ID: 7536288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of Bordetella pertussis infection with monoclonal antibodies to pertussis toxin.
    Halperin SA; Issekutz TB; Kasina A
    J Infect Dis; 1991 Feb; 163(2):355-61. PubMed ID: 1703192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of proteolytic enzymes, storage and reduction on the structure and biological activity of pertussigen, a toxin from Bordetella pertussis.
    Peppler MS; Judd RC; Munoz JJ
    Dev Biol Stand; 1985; 61():75-87. PubMed ID: 3914965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
    Askelöf P; Rodmalm K; Wrangsell G; Larsson U; Svenson SB; Cowell JL; Undén A; Bartfai T
    Proc Natl Acad Sci U S A; 1990 Feb; 87(4):1347-51. PubMed ID: 2304902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough.
    Nencioni L; Pizza M; Bugnoli M; De Magistris T; Di Tommaso A; Giovannoni F; Manetti R; Marsili I; Matteucci G; Nucci D
    Infect Immun; 1990 May; 58(5):1308-15. PubMed ID: 2323818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of T- and B-cell epitopes of the S2 and S3 subunits of pertussis toxin by use of synthetic peptides.
    Chong P; Zobrist G; Sia C; Loosmore S; Klein M
    Infect Immun; 1992 Nov; 60(11):4640-7. PubMed ID: 1383153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A quantitative analysis for the ADP-ribosylation activity of pertussis toxin: an enzymatic-HPLC coupled assay applicable to formulated whole cell and acellular pertussis vaccine products.
    Cyr T; Menzies AJ; Calver J; Whitehouse LW
    Biologicals; 2001 Jun; 29(2):81-95. PubMed ID: 11580213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Site-specific alterations in the B oligomer that affect receptor-binding activities and mitogenicity of pertussis toxin.
    Lobet Y; Feron C; Dequesne G; Simoen E; Hauser P; Locht C
    J Exp Med; 1993 Jan; 177(1):79-87. PubMed ID: 8418210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of murine monoclonal antibodies that recognize defined epitopes of pertussis toxin and neutralize its toxic effect on Chinese hamster ovary cells.
    Walker MJ; Wehland J; Timmis KN; Raupach B; Schmidt MA
    Infect Immun; 1991 Nov; 59(11):4249-51. PubMed ID: 1718872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies that define neutralizing epitopes of pertussis toxin: conformational dependence and epitope mapping.
    Lang AB; Ganss MT; Cryz SJ
    Infect Immun; 1989 Sep; 57(9):2660-5. PubMed ID: 2474500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.